ArticleInvestigational new drugs2026
First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors.
Article in Investigational new drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05582850 (A Phase 1, Multicentre, Open-label, Dose-escalation and Expansion Study to Determine a Recommended Phase 2 Dose), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Multicentre, Open-label, Dose-escalation and Expansion Study to Determine a Recommended Phase 2 Dose (RP2D) of DT-9081 in Participants With Advanced Solid Tumours
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DT-9081 is a selective antagonist of the prostaglandin E2 receptor EP4, developed to counteract tumor-driven immunosuppression. This first-in-human phase I study aimed at determining the dose-limiting toxicity/maximum tolerated dose (DLT/MTD) of DT-9081 and identifying the recommended phase II dose (RP2D) in patients with advanced solid tumors. This open-label, dose-escalation study enrolled patients with advanced (unresectable, recurrent or metastatic) solid tumors refractory to standard therapies. DT-9081 was administered orally once daily across six sequential dose cohorts (25-600 mg, daily). Primary objectives were safety and determination of the RP2D. Secondary objectives included efficacy, pharmacokinetics (PK) characterization, and pharmacodynamic (PD) assessment. Twenty-nine patients were treated. One dose-limiting toxicity (grade 3 increased hepatic enzymes) was observed at the 50 mg dose level. The most frequently reported treatment-emergent adverse events (TEAEs) were diarrhea (55.2%), decreased appetite (24.1%), nausea (20.7%), vomiting (20.7%), and asthenia (20.7%). Most TEAEs were grade 1-2. Grade ≥ 3 DT-9081-related adverse events occurred in 2 (6.9%) patients (grade 3 diarrhea and grade 3 increased hepatic enzymes). DT-9081 exhibited dose-proportional PK with sustained plasma exposure exceeding preclinical IC50 thresholds at higher dose levels. Pharmacodynamic analyses demonstrated dose-dependent reversal of EP4-mediated suppression of TNF-α production, confirming target engagement. Based on integrated safety, PK, and PD data, 600 mg once daily was selected as the RP2D, despite the absence of meaningful clinical activity. MTD was not reached and pharmacodynamic activity was consistent with EP4R antagonism. These findings support further clinical development of DT-9081, including evaluation in immunotherapy-based combination regimens.EUCT Number: 2024-516206-28-00;NCT05582850.Study registration date: 10/10/2022.
Indexed as
Identifiers
42734705What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.